CANCER MONOCLONAL ANTIBODIES MARKET Challenges and Opportunities

The high treatment cost of monoclonal antibodies (mAbs) hampers market development by limiting patient accessibility and placing financial strain on healthcare systems, especially in low- and middle-income countries. For instance, KEYTRUDA (Pembrolizumab), the list price for each indicated dose of KEYTRUDA when given every 3 weeks is US$ 11,337.36. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is US$ 22,674.72. Additionally, most of these countries lack proper health coverage for monoclonal antibody therapies, thereby hindering the market development in the emerging markets.

Market Opportunity – Launch of efficient bioreactors to increase production

The launch of efficient bioreactors to increase production can provide significant opportunities for the cancer monoclonal antibodies market in the coming years. For instance, in April 2023, Cytiva, a global provider of healthcare solutions, services, and expertise, launched X-platform bioreactors to simplify upstream bioprocessing activities that are used just once. X-platform bioreactors, initially available in 50 and 200 L capacities, come equipped with Figurate automation solution software and can improve process efficiency through ergonomic improvements, production capability, and streamlined supply chain operations.